Diversified Trust Co Lowers Stock Holdings in Penumbra, Inc. (NYSE:PEN)

Diversified Trust Co decreased its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 38.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,276 shares of the company's stock after selling 3,993 shares during the quarter. Diversified Trust Co's holdings in Penumbra were worth $1,678,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in PEN. RTW Investments LP raised its stake in shares of Penumbra by 8.4% during the 4th quarter. RTW Investments LP now owns 862,450 shares of the company's stock valued at $204,815,000 after purchasing an additional 66,700 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in Penumbra by 47.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company's stock valued at $167,913,000 after buying an additional 227,506 shares in the last quarter. Bank of America Corp DE grew its holdings in Penumbra by 19.9% during the 4th quarter. Bank of America Corp DE now owns 346,528 shares of the company's stock valued at $82,293,000 after buying an additional 57,421 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Penumbra by 23.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 323,964 shares of the company's stock valued at $76,937,000 after buying an additional 60,764 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Penumbra by 20.8% in the fourth quarter. Northern Trust Corp now owns 318,230 shares of the company's stock worth $75,573,000 after buying an additional 54,890 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company's stock.

Penumbra Trading Down 2.1%

Penumbra stock traded down $5.44 during trading hours on Tuesday, reaching $251.19. The stock had a trading volume of 293,623 shares, compared to its average volume of 450,808. The company has a fifty day simple moving average of $272.16 and a 200-day simple moving average of $268.26. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The stock has a market cap of $9.73 billion, a PE ratio of 237.10, a PEG ratio of 2.28 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.30 and a quick ratio of 3.68.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. Penumbra had a return on equity of 11.14% and a net margin of 3.41%. The company had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. During the same quarter in the previous year, the business earned $0.41 EPS. Penumbra's revenue was up 16.3% compared to the same quarter last year. Analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on PEN. Wall Street Zen raised shares of Penumbra from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 14th. Stifel Nicolaus set a $318.00 price target on shares of Penumbra and gave the company a "buy" rating in a research report on Thursday, April 24th. Truist Financial increased their price objective on Penumbra from $315.00 to $330.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. BTIG Research restated a "buy" rating on shares of Penumbra in a research report on Thursday, April 24th. Finally, Royal Bank Of Canada increased their price target on shares of Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $302.40.

Insider Buying and Selling

In other news, Director Arani Bose sold 12,000 shares of Penumbra stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $298.73, for a total transaction of $3,584,760.00. Following the sale, the director owned 302,819 shares of the company's stock, valued at approximately $90,461,119.87. The trade was a 3.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bridget O'rourke sold 100 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $286.15, for a total transaction of $28,615.00. Following the completion of the transaction, the director directly owned 5,423 shares of the company's stock, valued at approximately $1,551,791.45. The trade was a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 131,135 shares of company stock valued at $36,188,345 over the last three months. Insiders own 5.00% of the company's stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.